Current approaches to the management of osteoporosis in men

American Journal of Health-System Pharmacy

Volumn 61, Issue 17, 2004, Pages 1801-1811

  Vondracek, Sheryl Follin ^a,b,c,d   Hansen, Laura B ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ELI LILLY   (United States)

^d W Ctrl Regional Osteoporosis Board   (United States)

Author keywords

Alcohols, ethyl; Alendronate sodium; Androgens; Calcitonin; Calcium; Calcium regulators; Costs; Diagnosis; Dosage schedules; Epidemiology; Exercise; Hormones; Men; Minerals; Mortality; Osteoporosis; Parathyroid hormones; Protocols; Smoking; Teriparatide; Testosterone

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; GLUCOCORTICOID; HYDROCHLOROTHIAZIDE; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; TESTOSTERONE; THIAZIDE DIURETIC AGENT; VITAMIN D;

ABDOMINAL PAIN; ACNE; ALCOHOL CONSUMPTION; ALCOHOLISM; AZOOSPERMIA; CALCIUM INTAKE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; DYSPEPSIA; EDEMA; ENTERITIS; EXERCISE; FRACTURE; GYNECOMASTIA; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPOGONADISM; IMMOBILIZATION; KIDNEY DISEASE; LABORATORY TEST; LEG CRAMP; LIVER DISEASE; MALE; MORBIDITY; MORTALITY; ORGAN TRANSPLANTATION; OSTEOPOROSIS; PATHOPHYSIOLOGY; POLYCYTHEMIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE DISEASE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SKIN MANIFESTATION; SLEEP APNEA SYNDROME; SMOKING CESSATION; VITAMIN INTAKE; WEIGHT GAIN;

EID: 8344232468     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.17.1801     Document Type: Review

References (122)

1. Follin SL, Hansen LB. Current approaches to the prevention and treatment of postmenopausal osteoporosis. Am J Health Syst-Pharm. 2003; 60:883-901.
2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001; 285: 785-95.
3. Eichner SF, Lloyd KB, Timpe EM. Comparing therapies for postmenopausal osteoporosis prevention and treatment. Ann Pharmacother. 2003; 37:711-24.
4. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. www.nof.org/ physguide/index.htm (accessed 2003 Jul 23).
5. Hodgson SF, Watts NB, Bilezikian JP et al. American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis. Endocr Pract. 2001; 7:293-312.
6. North American Menopause Society. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause. 2002; 9:84-101.
7. National Osteoporosis Foundation. America's bone health: the state of osteoporosis and low bone mass. www. nof.org/advocacy/prevalence/index.htm (accessed 2003 Jul 21).
8. Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone. 1995; 17(5 suppl):S505-11.
9. Orwoll ES, Klein R. Osteoporosis in men. Epidemiology, pathophysiology, and clinical characterization. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. 2nd ed. San Diego: Academic Press; 2001:103-49.
10. Ray NF, Chan JK, Thamer M et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997; 12:24-35.
11. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002; 359:1761-7.
12. Trombetti A, Herrmann F, Hoffmeyer P et al. Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int. 2002; 13:731-7.
13. O'Neill TW, Cooper C, Finn JD et al. Incidence of distal forearm fracture in British men and women. Osteoporos Int. 2001; 12:555-8.
14. Jacobsen SJ, Goldberg J, Miles TP et al. Hip fracture incidence among the old and very old: a population-based study of 745,435 cases. Am J Public Health. 1990; 80:871-3.
15. Cooper C, Atkinson EJ, O'Fallon WM et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res. 1992; 7:221-7.
16. Center JR, Nguyen TV, Schneider D et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999; 353:878-82.
17. Office of Technology Assessment. Hip fracture outcomes in people age 50 and older - background paper, OTA-BP-H 120. Washington, DC: U.S. Government Printing Office; 1994 Jul.
18. Cooper C, Atkinson EJ, Jacobsen SJ et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol. 1993; 137:1001-5.
19. Klotzbuecher CM, Ross PD, Landsman PB et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000; 15:721-39.
20. Melton LJ 3rd, Atkinson EJ, Cooper C et al. Vertebral fractures predict subsequent fractures. Osteoporos Int. 1999; 10: 214-21.
21. Siddiqui NA, Shetty KR, Duthie EH Jr. Osteoporosis in older men: discovering when and how to treat it. Geriatrics. 1999; 54:20-2,27-8,30 passim.
22. Szulc P, Munoz F, Claustrat B et al. Bioavailable estradiol may be an important determinant of Osteoporosis in men: the MINOS study. J Clin Endocrinol Metab. 2001; 86:192-9.
23. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001; 22:477-501.
24. Harris SS, Soteriades E, Coolidge JA et al. Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population. J Clin Endocrinol Metab. 2000; 85:4125-30.
25. Boonen S, Vanderschueren D, Cheng XG et al. Age-related (type II) femoral neck Osteoporosis in men: biochemical evidence for both hypovitaminosis D-and androgen deficiency-induced bone resorption. J Bone Miner Res. 1997; 12: 2119-26.
26. Basaria S, Dobs AS. Hypogonadism and androgen replacement therapy in elderly men. Am J Med. 2001; 110:563-72.
27. Seeman E. Pathogenesis of bone fragility in women and men. Lancet. 2002; 359:1841-50.
28. Mosekilde L. Sex differences in age-related loss of vertebral trabecular bone mass and structure-biomechanical consequences. Bone. 1989; 10:425-32.
29. O'Neill TW, Varlow J, Silman AJ et al. Age and sex influences on fall characteristics. Ann Rheum Dis. 1994; 53:773-5.
30. Graafmans WC, Ooms ME, Hofstee HM et al. Falls in the elderly, a prospective study of risk factors and risk profiles. Am J Epidemiol. 1996; 143:1129-36.
31. Gennari L, Brandi ML. Genetics of male osteoporosis. Calcif Tissue Int. 2001; 69:200-4.
32. Huuskonen J, Vaisanen SB, Kroger H et al. Determinants of bone mineral density in middle aged men: a population-based study. Osteoporos Int. 2000; 11:702-8.
33. Francis RM. Androgen replacement in aging men. Calcif Tissue Int. 2001; 69:235-8.
34. Szulc P, Garnero P, Claustrat B et al. Increased bone resorption in moderate smokers with low body weight: the MINOS study. J Clin Endocrinol Metab. 2002; 87:666-74.
35. Kiel DP, Zhang Y, Hannan MT et al. The effect of smoking at different life stages on bone mineral density in elderly men and women. Osteoporos Int. 1996; 6:240-8.
36. Burger H, de Laet CE, van Daele PL et al. Risk factors for increased bone loss in an elderly population: the Rotterdam study. Am J Epidemiol. 1998; 147:871-9.
37. Burgess E, Nanes MS. Osteoporosis in men: pathophysiology, evaluation, and therapy. Curr Opin Rheumatol. 2002; 14:421-8.
38. Tanaka T, Latorre MR, Jaime PC et al. Risk factors for proximal femur osteoporosis in men aged 50 years or older. Osteoporos Int. 2001; 12:942-9.
39. Nguyen TV, Eisman JA, Kelly PJ et al. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol. 1996; 144:255-63.
40. Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int. 2000; 11:192-202.
41. Binkley NC, Schmeer P, Wasnich RD et al. What are the criteria by which a densitometric diagnosis of osteoporosis can be made in males and non-Caucasians? J Clin Densitom. 2002; 5(suppl):S19-27.
42. International Society for Clinical Densitometry. Official positions of the ISCD. www.iscd.org/official.cfm (accessed 2003 Jul 21).
43. Kanis JA, Delmas P, Burckhardt P et al. Guidelines for diagnosis and management of osteoporosis. Osteoporos Int. 1997; 7:390-406.
44. Orwoll ES, Scheele WH, Paul S et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003; 18:9-17.
45. Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab. 2001; 86:5252-5.
46. Orwoll E, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343:604-10.
47. Orwoll E. Assessing bone density in men. J Bone Miner Res. 2000; 15:1867-70.
48. Miller PD, Njeh CF, Jankowski LG et al. What are the standards by which bone mass measurement at peripheral skeletal sites should be used in the diagnosis of osteoporosis? J Clin Densitom. 2002; 5(suppl):S39-45.
49. Wuster C, Hadji P. Use of quantitative ultrasound densitometry (QUS) in male osteoporosis. Calcif Tissue Int. 2001; 69:225-8.
50. Nguyen TV, Center JR, Eisman JA. Osteoporosis in elderly men and women: effects of dietary calcium, physical activity, and body mass index. J Bone Miner Res. 2000; 15:322-31.
51. Guideline for the prevention of falls in older persons. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. J Am Geriatr Soc. 2001; 49:664-72.
52. Grisso JA, Kelsey JL, O'Brien LA et al. Risk factors for hip fracture in men. Am J Epidemiol. 1997; 145:786-93.
53. Slemenda CW, Christian JC, Reed T et al. Long-term bone loss in men: effects of genetic and environmental factors. Ann Intern Med. 1992; 117:286-91.
54. Paganini-Hill A, Chao A, Ross RK et al. Exercise and other factors in the prevention of hip fracture: the Leisure World study. Epidemiology. 1991; 2:16-25.
55. Hoidrup S, Prescott E, Sorensen TI et al. Tobacco smoking and risk of hip fracture in men and women. Int J Epidemiol. 2000; 29:253-9.
56. Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int. 2001; 68:259-70.
57. Felson DT, Kiel DP, Anderson JJ et al. Alcohol consumption and hip fractures: the Framingham study. Am J Epidemiol. 1988; 128:1102-10.
58. Felson DT, Zhang Y, Hannan MT et al. Alcohol intake and bone mineral density in elderly men and women: the Framingham study. Am J Epidemiol. 1995; 142:485-92.
59. Peris P, Pares A, Guanabens N et al. Reduced spinal and femoral bone mass and deranged bone mineral metabolism in chronic alcoholics. Alcohol Alcohol. 1992; 27:619-25.
60. Gonzalez-Calvin JL, Garcia-Sanchez A, Bellot V et al. Mineral metabolism, osteoblastic function and bone mass in chronic alcoholism. Alcohol Alcohol. 1993; 28:571-9.
61. Holbrook TL, Barrett-Connor E. A prospective study of alcohol consumption and bone mineral density. BMJ. 1993; 306:1506-9.
62. Diamond T, Stiel D, Lunzer M et al. Ethanol reduces bone formation and may cause osteoporosis. Am J Med. 1989; 86:282-8.
63. Laitinen K, Lamberg-Allardt C, Tunninen R et al. Bone mineral density and abstention-induced changes in bone and mineral metabolism in noncirrhotic male alcoholics. Am J Med. 1992; 93: 642-50.
64. Chilibeck PD, Sale DG, Webber CE. Exercise and bone mineral density. Sports Med. 1995; 19:103-22.
65. Karlsson MK. Skeletal effects of exercise in men. Calcif Tissue Int. 2001; 69:196-9.
66. Smith EL, Gilligan C. Physical activity effects on bone metabolism. Calcif Tissue Int. 1991; 49(suppl):S50-4.
67. Gregg EW, Pereira MA, Caspersen CJ. Physical activity, falls, and fractures among older adults: a review of the epidemiologic evidence. J Am Geriatr Soc. 2000; 48:883-93.
68. Joakimsen RM, Fonnebo V, Magnus JH et al. The Tromso study: physical activity and the incidence of fractures in a middle-aged population. J Bone Miner Res. 1998; 13:1149-57.
69. Lips P, Graafmans WC, Ooms ME et al. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med. 1996; 124:400-6.
70. Peacock M, Liu G, Carey M et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab. 2000; 85:3011-9.
71. Recker RR, Hinders S, Davies KM et al. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res. 1996; 11: 1961-6.
72. Reid IR, Ames RW, Evans MC et al. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med. 1995; 98:331-5.
73. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ. 2003; 326:469-72.
74. Chapuy MC, Arlot ME, Duboeuf F et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992; 327:1637-42.
75. Dawson-Hughes B, Harris SS, Krall EA et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997; 337:670-6.
76. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, and the Institute of Medicine. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press; 1997.
77. NIH Consensus Development Panel on Optimal Calcium Intake. Optimal calcium intake. JAMA. 1994; 272:1942-8.
78. Wright J, Wang C, Kennedy-Stephenson J et al. Dietary intake often key nutrients for public health, United States: 1999-2000. Advance data from vital and health statistics. Hyattsville, MD: National Center for Health Statistics; 2003.
79. Lo CW, Paris PW, Clemens TL et al. Vitamin D absorption in healthy subjects and in patients with intestinal malabsorption syndromes. Am J Clin Nutr. 1985; 42:644-9.
80. Elliott ME, Binkley NC, Carnes M et al. Fracture risks for women in long-term care: high prevalence of calcaneal osteoporosis and hypovitaminosis D. Pharmacothempy. 2003; 23:702-1-0.
81. Thomas MK, Lloyd-Jones DM, Thadhani RI et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998; 338:777-83.
82. Van der Wielen RP, Lowik MR, van den Berg H et al. Serum vitamin D concentrations among elderly people in Europe. Lancet. 1995; 346:207-10.
83. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet. 1998; 351:805-6. Letter.
84. Barger-Lux MJ, Heaney RP, Dowell S et al. Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporos Int. 1998; 8: 222-30.
85. Adams JS, Kantorovich V, Wu C et al. Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density. J Clin Endocrinol Metab. 1999; 84:2729-30.
86. Dunn CJ, Goa KL. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease. Drugs. 2001; 61:685-712.
87. Ho YV, Frauman AG, Thomson W et al. Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int. 2000; 11:98-101.
88. Reid DM, Hughes RA, Laan RF et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000; 15:1006-13.
89. Reid DM, Adami S, Devogelaer JP et al. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int. 2001; 69:242-7.
90. Cohen S, Levy RM, Keller M et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999; 42:2309-18.
91. Wallach S, Cohen S, Reid DM et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000; 67:277-85.
92. Ringe J, Dorst A, Faber H. Risedronate reduces vertebral fractures in men with osteoporosis. J Bone Miner Res. 2003; 18:SA355. Abstract
93. Gordon MS, Gordon MB, Delaney M et al. Once weekly administration of risedronate for the treatment of osteoporosis in men. Paper presented at Endocrine Society 85th Annual Meeting. Philadelphia, PA; 2003.
94. Sharpe M, Noble S, Spencer CM. Alendronate: an update of its use in osteoporosis. Drugs. 2001; 61:999-1039.
95. Rubin MR, Cosman F, Lindsay R et al. The anabolic effects of parathyroid hormone. Osteoporos Int. 2002; 13:267-77.
96. Kurland ES, Cosman F, McMahon DJ et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000; 85: 3069-76.
97. Forteo (teriparatide) package insert. Indianapolis, IN: Eli Lilly and Co.; 2002 Dec.
98. Howell S, Shalet S. Testosterone deficiency and replacement. Horm Res. 2001; 56(suppl 1):S86-92.
99. Barrett-Connor E, Mueller JE, von Muhlen DG et al. Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2000; 85:219-23.
100. Stanley HL, Schmitt BP, Poses RM et al. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J Am Geriatr Soc. 1991; 39:766-71.
101. Behre HM, Kliesch S, Leifke E et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 1997; 82: 2386-90.
102. Katznelson L, Finkelstein JS, Schoenfeld DA et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996; 81:4358-65.
103. Wang C, Cunningham G, Dobs A et al. Long-term testosterone gel (Andro Gel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density. J Clin Endocrinol Metab. 2004; 89:2085-98.
104. American Association of Clinical Endocrinologists Hypogonadism Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocr Pract. 2002; 8:439-56.
105. Anderson FH, Francis RM, Peaston RT et al. Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption. J Bone Miner Res. 1997; 12:472-8.
106. Snyder PJ, Peachey H, Hannoush P et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999; 84: 1966-72.
107. Anderson FH, Francis RM, Faulkner K. Androgen supplementation in eugonadal men with osteoporosis - effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone. 1996; 18:171-7.
108. Trovas GP, Lyritis GP, Galanos A et al. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res. 2002; 17:521-7.
109. Gennari C. Analgesic effect of calcitonin in osteoporosis. Bone. 2002; 30:675-70S.
110. Lyritis GP, Paspati I, Karachalios T et al. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl. 1997; 275:112-4.
111. Pun KK, Chan LW. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther. 1989; 11:205-9.
112. Cauley JA, Cummings SR, Seeley DG et al. Effects of thiazide diuretic therapy on bone mass, fractures, and falls. Ann Intern Med. 1993; 118:666-73.
113. Schoofs MW, van der Klift M, Hofman A et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med. 2003; 139: 476-82.
114. Herings RM, Stricker BH, de Boer A et al. Current use of thiazide diuretics and prevention of femur fractures. J Clin Epidemiol. 1996; 49:115-9.
115. Morton DJ, Barrett-Connor EL, Edelstein SL. Thiazides and bone mineral density in elderly men and women. Am J Epidemiol. 1994; 139:1107-15.
116. Reid IR, Ames RW, Orr-Walker BJ et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med. 2000; 109:362-70.
117. LaCroix AZ, Ott SM, Ichikawa L et al. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000; 133:516-26.
118. LaCroix AZ, Wienpahl J, White LR et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med. 1990; 322:286-90.
119. Felson DT, Sloutskis D, Anderson JJ et al. Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study. JAMA. 1991; 265:370-3.
120. Adams JS, Song CF, Kantorovich V. Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydrochlorothiazide. Ann Intern Med. 1999; 130:658-60.
121. Finkelstein JS, Hayes A, Hunzelman JL et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003; 349: 1216-26.
122. Follin SL. Update in osteoporosis. In: Mueller B, Bertch K, Dunsworth T et al., eds. Pharmacotherapy self-assessment program, 4th ed. Men's health module. Kansas City, MO: American College of Clinical Pharmacy; 2003:350.